Clinical Trial Update: Phase III ALTU-135 CP Safety Trial [Phase 3]

View source ↗

Summary

Phase III safety trial ALTU-135 CP for exocrine pancreatic insufficiency was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Exocrine Pancreatic Insufficiency

Drugs mentioned

• ALTU-135 CP

Snippet

Sponsor: Anthera Pharmaceuticals | Conditions: Exocrine Pancreatic Insufficiency | Phase 3 | Status: TERMINATED